SIGA Stock Overview
A commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
SIGA Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.25 |
| 52 Week High | US$12.83 |
| 52 Week Low | US$4.26 |
| Beta | 0.89 |
| 11 Month Change | -9.16% |
| 3 Month Change | -33.08% |
| 1 Year Change | 17.04% |
| 33 Year Change | -29.54% |
| 5 Year Change | 26.01% |
| Change since IPO | 19.05% |
Recent News & Updates
Investors Shouldn't Be Too Comfortable With SIGA Technologies' (NASDAQ:SIGA) Earnings
Nov 15
SIGA Technologies, Inc. (NASDAQ:SIGA) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 14SIGA Technologies: Shares Tanking On Mpox Study Miss, Turbulence May Be Temporary
Aug 15SIGA Technologies, Inc. (NASDAQ:SIGA) Held Back By Insufficient Growth Even After Shares Climb 31%
Jul 14Recent updates
Investors Shouldn't Be Too Comfortable With SIGA Technologies' (NASDAQ:SIGA) Earnings
Nov 15SIGA Technologies, Inc. (NASDAQ:SIGA) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 14SIGA Technologies: Shares Tanking On Mpox Study Miss, Turbulence May Be Temporary
Aug 15SIGA Technologies, Inc. (NASDAQ:SIGA) Held Back By Insufficient Growth Even After Shares Climb 31%
Jul 14SIGA Technologies: BARDA Contract Renewal Required To Sustain Recent Momentum (Rating Downgrade)
Jun 13SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company
Mar 31Siga Technologies: Preparing For A Contingency If Tomorrow Comes
Mar 25Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality
Mar 19The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)
Feb 15Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?
Jan 13SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX
Sep 29Siga monkeypox therapy undergoes NIH-led late-stage trial
Sep 09Scientists behind key COVID study run monkeypox trial for SIGA therapy
Aug 23SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg
Aug 17Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)
Aug 12SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise
Aug 09SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play
Aug 01SIGA Technologies: Buy Monkeypox
Jul 25Siga Technologies receives approval from UK for tecovirimat
Jul 08SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak
May 27SIGA Technologies: There's An Assured Market For A Smallpox Vaccine
Dec 12It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year
Jun 08SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX
Apr 28Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years
Feb 22We're Not So Sure You Should Rely on SIGA Technologies' (NASDAQ:SIGA) Statutory Earnings
Feb 02Shareholder Returns
| SIGA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.4% | -5.3% | -1.2% |
| 1Y | 17.0% | 8.7% | 30.4% |
Return vs Industry: SIGA exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: SIGA underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SIGA volatility | |
|---|---|
| SIGA Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SIGA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SIGA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 45 | Diem Nguyen | www.siga.com |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
SIGA Technologies, Inc. Fundamentals Summary
| SIGA fundamental statistics | |
|---|---|
| Market cap | US$446.99m |
| Earnings (TTM) | US$85.71m |
| Revenue (TTM) | US$173.73m |
5.2x
P/E Ratio2.6x
P/S RatioIs SIGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIGA income statement (TTM) | |
|---|---|
| Revenue | US$173.73m |
| Cost of Revenue | US$43.55m |
| Gross Profit | US$130.19m |
| Other Expenses | US$44.48m |
| Earnings | US$85.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 74.93% |
| Net Profit Margin | 49.33% |
| Debt/Equity Ratio | 0% |
How did SIGA perform over the long term?
See historical performance and comparison